Publications
Export 8 results:
Auteur Title [ Type
Filtres: Auteur is Meyer, Pierre-François [Enlever les filtres]
AD molecular: PET amyloid imaging across the Alzheimer's disease spectrum: From disease mechanisms to prevention.. Prog Mol Biol Transl Sci. 165:63-106.
.
2019. Association of a Total Cholesterol Polygenic Score with Cholesterol Levels and Pathological Biomarkers across the Alzheimer's Disease Spectrum.. Genes (Basel). 12(11)
.
2021. Bi-directional Association of Cerebrospinal Fluid Immune Markers with Stage of Alzheimer's Disease Pathogenesis.. J Alzheimers Dis. 63(2):577-590.
.
2018. Dementia risk reduction: why haven't the pharmacological risk reduction trials worked? An in-depth exploration of seven established risk factors. Alzheimers Dement (N Y). 7(1):e12202.
.
2021. Hypothesis: cerebrospinal fluid protein markers suggest a pathway toward symptomatic resilience to AD pathology.. Alzheimers Dement. 15(9):1160-1171.
.
2019. INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease.. Neurology. 92(18):e2070-e2080.
.
2019. No apparent effect of naproxen on CSF markers of innate immune activation.. Ann Clin Transl Neurol. 6(6):1127-1133.
.
2019. .
2021.